Pharmala Biotech (MDMA) Q1 2026 earnings summary

Executive summary

• Major steps taken in late 2025 and Q1 2026 to advance novel molecule development, aiming to start Phase 2a/b clinical trials in Australia.

• Demand for LaNeo MDMA continues to grow, expanding the clinical trial sales pipeline.

• Approval of reimbursement for LaNeo MDMA treatments in Australia by private insurers and the Department of Veterans Affairs is expected to drive further growth.

Financial highlights

• Customer deposits increased by $150k in year-end 2025, offset by $83k recognized revenue, totaling $276k compared to $209k a year earlier.

• Q1 2026 saw a $225k increase in deposits, offset by $68k recognized revenue, totaling $433k compared to $276k at the end of 2025.

• Deposits typically represent 50% of contract value and are recognized as revenue upon product shipment, pending regulatory permits.

Outlook and guidance

• Anticipates continued momentum in molecule development and clinical trial progress throughout fiscal 2026.

• Expects growth in clinical trial revenue pipeline and customer deposits, supported by new funding and reimbursement approvals.